Hyperacidity, GERD, and ulcers:
Indications for: ROBINUL FORTE
Adjunct in peptic ulcer.
Limitations of Use:
Not indicated as monotherapy for treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established.
Use lowest effective dose. 2mg 2–3 times daily in divided doses; max 8mg daily. Not recommended for patients in whom a lower dosage strength of oral glycopyrrolate is appropriate for initial or maintenance treatment.
ROBINUL FORTE Contraindications:
Glaucoma. Obstructive uropathies, including prostatic hypertrophy. Mechanical obstructive diseases of the GI tract (eg, pyloroduodenal stenosis, strictures). GI motility disorders (eg, achalasia, paralytic ileus, intestinal atony). Bleeding GI ulcer. Active inflammatory or infectious colitis. Toxic megacolon. Myasthenia gravis.
ROBINUL FORTE Warnings/Precautions:
Precipitation of acute glaucoma. IOP. Partial or complete mechanical intestinal obstruction. Ileostomy. Colostomy. Monitor for decreased GI motility. Cognitive or visual impairment. Conditions exacerbated by anticholinergic effects (eg, autonomic neuropathy, hyperthyroidism, cardiac disease, hiatal hernia due to reflux esophagitis). Avoid exposure to hot or very warm environmental temperatures. Renal impairment: monitor. Increased risk of anticholinergic adverse reactions in elderly (≥65yrs): not recommended. Pregnancy. Nursing mothers.
ROBINUL FORTE Classification:
ROBINUL FORTE Interactions:
Additive anticholinergic effects with other anticholinergics (eg, tricyclics, antiepileptics, class I antiarrhythmics, antispasmodics, amantadine) or other medications that decrease GI motility: not recommended. Concomitant use with solid oral dosage forms of potassium chloride may worsen GI mucosal injury due to decreased gastric motility and increased transit time: not recommended.
Blurred vision, drowsiness, decreased sweating, flushing, vomiting, constipation, dry mouth, tachycardia, urinary retention.
Renal. Half-life: 3 hours.
Generic Drug Availability: